# Radiotherapy With Cisplatin Versus Radiotherapy With Cetuximab After Induction Chemotherapy for Larynx Preservation

> **NCT00169247** · PHASE2 · COMPLETED · sponsor: **Groupe Oncologie Radiotherapie Tete et Cou** · enrollment: 156 (estimated)

## Conditions studied

- Larynx Cancer
- Hypopharynx Cancer

## Interventions

- **DRUG:** cetuximab
- **DRUG:** Cisplatin
- **PROCEDURE:** Radiotherapy 70 Gy, 35 fractions

## Key facts

- **NCT ID:** NCT00169247
- **Lead sponsor:** Groupe Oncologie Radiotherapie Tete et Cou
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-10
- **Primary completion:** 2011-04
- **Final completion:** —
- **Target enrollment:** 156 (ESTIMATED)
- **Last updated:** 2011-06-27

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00169247

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00169247, "Radiotherapy With Cisplatin Versus Radiotherapy With Cetuximab After Induction Chemotherapy for Larynx Preservation". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT00169247. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*